» Articles » PMID: 35734939

C3 Glomerulopathy: Understanding an Ultra-rare Complement-mediated Renal Disease

Overview
Specialty Genetics
Date 2022 Jun 23
PMID 35734939
Authors
Affiliations
Soon will be listed here.
Abstract

C3 glomerulopathy (C3G) describes a pathologic pattern of injury diagnosed by renal biopsy. It is characterized by the dominant deposition of the third component of complement (C3) in the renal glomerulus as resolved by immunofluorescence microscopy. The underlying pathophysiology is driven by dysregulation of the alternative pathway of complement in the fluid-phase and in the glomerular microenvironment. Characterization of clinical features and a targeted evaluation for indices and drivers of complement dysregulation are necessary for optimal patient care. Autoantibodies to the C3 and C5 convertases of complement are the most commonly detected drivers of complement dysregulation, although genetic mutations in complement genes can also be found. Approximately half of patients progress to end-stage renal disease within 10 years of diagnosis, and, while transplantation is a viable option, there is high risk for disease recurrence and allograft failure. This poor outcome reflects the lack of disease-specific therapy for C3G, relegating patients to symptomatic treatment to minimize proteinuria and suppress renal inflammation. Fortunately, the future is bright as several anti-complement drugs are currently in clinical trials.

Citing Articles

Nearing the Finish Line: Steady Progress in the Development of Complement Inhibitors for Glomerular Disease.

Thurman J Kidney Int Rep. 2025; 10(2):302-305.

PMID: 39990875 PMC: 11843313. DOI: 10.1016/j.ekir.2024.11.1370.


Establishing the Future Direction of Clinical Outcomes in C3 Glomerulopathy: Perspectives From a Patient and a Physician.

Java A, Fuller L Kidney Med. 2025; 7(1):100928.

PMID: 39758154 PMC: 11699595. DOI: 10.1016/j.xkme.2024.100928.


Childhood onset C3 glomerulopathy: recurrence after kidney transplantation-a case series.

Borovitz Y, Landau D, Dagan A, Alfandari H, Haskin O, Levi S Front Pediatr. 2024; 12:1460525.

PMID: 39497737 PMC: 11532817. DOI: 10.3389/fped.2024.1460525.


Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group.

Nester C, Decker D, Meier M, Aslam S, Bomback A, Caravaca-Fontan F Clin J Am Soc Nephrol. 2024; .

PMID: 38829708 PMC: 11390019. DOI: 10.2215/CJN.0000000000000505.


Clinical and pathological features of 52 patients with glomerulonephritis with dominant C3.

Wei J, Huang Y, Yuan S, Chen X, Fu X, Li Z Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024; 49(1):75-83.

PMID: 38615169 PMC: 11017022. DOI: 10.11817/j.issn.1672-7347.2024.230328.


References
1.
Nester C, Smith R . Complement inhibition in C3 glomerulopathy. Semin Immunol. 2016; 28(3):241-9. DOI: 10.1016/j.smim.2016.06.002. View

2.
Sethi S, Gamez J, Vrana J, Theis J, Bergen 3rd H, Zipfel P . Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int. 2009; 75(9):952-60. PMC: 2738640. DOI: 10.1038/ki.2008.657. View

3.
Garam N, Cserhalmi M, Prohaszka Z, Szilagyi A, Veszeli N, Szabo E . FHR-5 Serum Levels and Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy. Front Immunol. 2021; 12:720183. PMC: 8461307. DOI: 10.3389/fimmu.2021.720183. View

4.
Michels M, Wijnsma K, Kurvers R, Westra D, Schreuder M, van Wijk J . Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort. Pediatr Nephrol. 2021; 37(3):601-612. PMC: 8921070. DOI: 10.1007/s00467-021-05221-6. View

5.
Habib R, Gubler M, Loirat C, Maiz H, Levy M . Dense deposit disease: a variant of membranoproliferative glomerulonephritis. Kidney Int. 1975; 7(4):204-15. DOI: 10.1038/ki.1975.32. View